NURS 610A Exam 2 Practice Test Bank | 2026/2027 Edition |
250 Verified Questions
NURS 610A Exam 2 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice test bank for NURS 610A Exam 2 at the University of Arizona contains
250 verified questions with correct answers and detailed rationales. Designed to mirror the actual exam
format, it covers key topics in advanced nursing practice, including pathophysiology, pharmacology,
and clinical management. Each question is aligned with the latest 2026-2027 curriculum guidelines to
ensure relevance and accuracy. Ideal for self-assessment and mastery of complex concepts.
Key Features:
Advanced Pathophysiology and Disease Mechanisms
Pharmacokinetics and Pharmacodynamics
Clinical Assessment and Diagnostic Reasoning
Evidence-Based Practice and Research Integration
Ethical and Legal Considerations in Advanced Practice
Health Promotion and Disease Prevention Strategies
Updates for 2026:
- Updated to reflect 2026-2027 AACN and University of Arizona curriculum changes
- Revised rationales to incorporate latest evidence-based guidelines
- Added new questions on emerging infectious diseases and telehealth
- Enhanced distractor explanations to clarify common misconceptions
- Aligned with updated NCLEX-RN and APRN competency standards
Abstract:
This practice test bank for NURS 610A Exam 2 at the University of Arizona comprises 250 meticulously verified
questions with correct answers and comprehensive rationales. The content is organized into major content areas
reflecting the course's focus on advanced nursing practice, including pathophysiology, pharmacology, clinical
assessment, and evidence-based interventions. Each question is designed to test higher-order thinking and clinical
reasoning skills, with rationales that explain both correct and incorrect options. The test bank has been updated
for the 2026-2027 academic year to incorporate the latest research, guidelines, and competency standards. It
serves as an essential resource for students preparing for the exam, offering a rigorous self-assessment tool that
mirrors the exam's format and difficulty. By engaging with these questions, students can identify knowledge gaps,
reinforce learning, and build confidence for success on the actual exam.
Keywords:
NURS 610A, Exam 2, Practice Test Bank, University of Arizona, Advanced Nursing Practice, Pathophysiology,
Pharmacology, Clinical Reasoning
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Incorrect
options are accompanied by brief explanations clarifying common errors or misconceptions. This format promotes
deep understanding and retention of key concepts.
Compliance Checklist:
All questions verified for accuracy by subject matter experts
Aligned with University of Arizona NURS 610A course objectives
Updated to reflect 2026-2027 academic year guidelines
Page 1
, Includes rationales for both correct and incorrect answers
Covers all major content areas weighted per exam blueprint
Formatted for easy self-assessment and review
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Pathophysiology 1-60 Cellular adaptation, inflammation, 24%
neoplasia, fluid/electrolyte imbalances,
acid-base disorders
Pharmacology 61-110 Pharmacokinetics, pharmacodynamics, 20%
autonomic nervous system drugs,
cardiovascular agents, antimicrobials
Clinical Assessment & 111-160 History taking, physical examination, 20%
Diagnostic Reasoning diagnostic tests interpretation, differential
diagnosis
Evidence-Based Practice & 161-200 Research designs, evidence appraisal, 16%
Research statistical concepts, applying evidence to
practice
Ethical & Legal Issues 201-225 Informed consent, confidentiality, advanced 10%
directives, malpractice, ethical
decision-making
Health Promotion & Disease 226-250 Screening guidelines, immunization, 10%
Prevention lifestyle counseling, population health
Page 2
,Q1. A 72-year-old patient with atrial fibrillation, hypertension, and type 2 diabetes is on warfarin, lisinopril,
metformin, and atorvastatin. The INR is 4.5. Which intervention is most appropriate?
A. Hold warfarin and administer vitamin K 10 mg orally
B. Hold warfarin and administer fresh frozen plasma
C. Hold warfarin, administer vitamin K 2.5 mg orally, and recheck INR in 24 hours
D. Continue warfarin at reduced dose
Correct Answer: C. Hold warfarin, administer vitamin K 2.5 mg orally, and recheck INR in 24 hours
Rationale: An INR of 4.5 without bleeding warrants holding warfarin and giving low-dose oral vitamin K (1-2.5
mg) to lower INR safely. High-dose vitamin K (10 mg) can cause warfarin resistance. Fresh frozen plasma is
reserved for major bleeding. Continuing warfarin risks hemorrhage.
Why Wrong:
A - High-dose vitamin K can lead to prolonged warfarin resistance and is not indicated without bleeding.
B - Fresh frozen plasma is indicated for serious or life-threatening bleeding, not for an elevated INR without
bleeding.
D - Continuing warfarin with an INR of 4.5 increases bleeding risk; dose reduction is insufficient acutely.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q2. Which of the following best explains why a patient with chronic kidney disease (eGFR 25 mL/min)
requires a lower dose of a drug that is primarily renally eliminated?
A. Increased volume of distribution leads to higher peak concentrations
B. Reduced renal clearance prolongs the elimination half-life
C. Decreased protein binding increases the free fraction of the drug
D. Hepatic metabolism is accelerated, necessitating dose adjustment
Correct Answer: B. Reduced renal clearance prolongs the elimination half-life
Rationale: In chronic kidney disease, reduced glomerular filtration decreases renal drug clearance, prolonging the
elimination half-life. To avoid accumulation and toxicity, doses must be reduced or intervals extended. Increased
volume of distribution (A) is not typical; protein binding changes (C) may occur but are less direct; hepatic
metabolism (D) may be impaired, not accelerated.
Why Wrong:
A - Volume of distribution is often decreased in renal impairment due to fluid shifts, not increased.
C - Decreased protein binding can increase free drug but is not the primary reason for dose adjustment; renal
clearance is the key.
D - Hepatic metabolism is often reduced, not accelerated, in renal disease.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 5
Q3. A patient on digoxin develops nausea, vomiting, and visual disturbances. Serum digoxin level is 3.5
ng/mL. Which of the following interventions is most appropriate?
A. Administer activated charcoal to enhance elimination
B. Administer digoxin immune Fab (Digibind)
C. Increase the dose of digoxin to overcome tolerance
D. Switch to a different cardiac glycoside
Correct Answer: B. Administer digoxin immune Fab (Digibind)
Rationale: Digoxin toxicity at this level with symptoms warrants digoxin immune Fab, which binds digoxin and
reduces free drug. Activated charcoal is not effective for digoxin once absorbed. Increasing dose would worsen
toxicity. Switching glycosides does not address current toxicity.
Why Wrong:
A - Activated charcoal is used for recent ingestion, not for toxicity from chronic therapy after absorption.
C - Increasing dose would exacerbate toxicity; tolerance does not develop to digoxin.
D - Switching to another glycoside is not indicated; management focuses on reversing toxicity.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38
Q4. A patient is prescribed an ACE inhibitor for hypertension. Which laboratory value should be monitored
before and during therapy?
A. Serum potassium and serum creatinine
B. Serum sodium and serum calcium
C. Liver enzymes and bilirubin
D. Hemoglobin and hematocrit
Correct Answer: A. Serum potassium and serum creatinine
Rationale: ACE inhibitors can cause hyperkalemia and acute kidney injury, especially in patients with renal
impairment or those taking potassium-sparing diuretics. Monitoring serum potassium and creatinine is essential.
Other labs are not typically affected.
Why Wrong:
B - ACE inhibitors do not significantly affect sodium or calcium levels.
C - ACE inhibitors do not cause hepatotoxicity; liver enzymes are not routinely monitored.
D - ACE inhibitors do not cause anemia; hemoglobin/hematocrit are not primary monitoring parameters.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 39
Q5. A patient on a stable dose of warfarin is prescribed a course of metronidazole for a dental infection.
What effect on the INR is expected?
A. Decrease in INR due to increased warfarin metabolism
B. Increase in INR due to inhibition of warfarin metabolism
C. No change in INR because metronidazole does not interact with warfarin
D. Unpredictable effect due to variable absorption
Correct Answer: B. Increase in INR due to inhibition of warfarin metabolism
Rationale: Metronidazole inhibits the hepatic metabolism of warfarin, potentiating its anticoagulant effect and
increasing INR. This interaction is well-documented and requires close monitoring and possible warfarin dose
reduction.
Why Wrong:
A - Metronidazole inhibits, not induces, warfarin metabolism.
C - Metronidazole has a significant interaction with warfarin.
D - The effect is predictable and not due to absorption variability.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q6. A patient with type 2 diabetes and chronic kidney disease (eGFR 45 mL/min) is prescribed metformin.
What is the primary concern?
A. Increased risk of hypoglycemia
B. Risk of lactic acidosis due to accumulation
C. Increased risk of weight gain
D. Reduced efficacy due to renal impairment
Correct Answer: B. Risk of lactic acidosis due to accumulation
Rationale: Metformin is contraindicated when eGFR is <30 mL/min and should be used with caution when eGFR is
30-45 mL/min due to risk of lactic acidosis from drug accumulation. Hypoglycemia is not common with metformin
monotherapy. Weight gain is not typical; metformin is weight-neutral or causes modest weight loss. Efficacy is not
significantly reduced.
Why Wrong:
A - Metformin does not typically cause hypoglycemia; it decreases hepatic glucose production.
C - Metformin is associated with weight neutrality or loss, not gain.
D - Metformin retains efficacy in moderate renal impairment, but safety is the concern.
Page 4
250 Verified Questions
NURS 610A Exam 2 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice test bank for NURS 610A Exam 2 at the University of Arizona contains
250 verified questions with correct answers and detailed rationales. Designed to mirror the actual exam
format, it covers key topics in advanced nursing practice, including pathophysiology, pharmacology,
and clinical management. Each question is aligned with the latest 2026-2027 curriculum guidelines to
ensure relevance and accuracy. Ideal for self-assessment and mastery of complex concepts.
Key Features:
Advanced Pathophysiology and Disease Mechanisms
Pharmacokinetics and Pharmacodynamics
Clinical Assessment and Diagnostic Reasoning
Evidence-Based Practice and Research Integration
Ethical and Legal Considerations in Advanced Practice
Health Promotion and Disease Prevention Strategies
Updates for 2026:
- Updated to reflect 2026-2027 AACN and University of Arizona curriculum changes
- Revised rationales to incorporate latest evidence-based guidelines
- Added new questions on emerging infectious diseases and telehealth
- Enhanced distractor explanations to clarify common misconceptions
- Aligned with updated NCLEX-RN and APRN competency standards
Abstract:
This practice test bank for NURS 610A Exam 2 at the University of Arizona comprises 250 meticulously verified
questions with correct answers and comprehensive rationales. The content is organized into major content areas
reflecting the course's focus on advanced nursing practice, including pathophysiology, pharmacology, clinical
assessment, and evidence-based interventions. Each question is designed to test higher-order thinking and clinical
reasoning skills, with rationales that explain both correct and incorrect options. The test bank has been updated
for the 2026-2027 academic year to incorporate the latest research, guidelines, and competency standards. It
serves as an essential resource for students preparing for the exam, offering a rigorous self-assessment tool that
mirrors the exam's format and difficulty. By engaging with these questions, students can identify knowledge gaps,
reinforce learning, and build confidence for success on the actual exam.
Keywords:
NURS 610A, Exam 2, Practice Test Bank, University of Arizona, Advanced Nursing Practice, Pathophysiology,
Pharmacology, Clinical Reasoning
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining why it is correct. Incorrect
options are accompanied by brief explanations clarifying common errors or misconceptions. This format promotes
deep understanding and retention of key concepts.
Compliance Checklist:
All questions verified for accuracy by subject matter experts
Aligned with University of Arizona NURS 610A course objectives
Updated to reflect 2026-2027 academic year guidelines
Page 1
, Includes rationales for both correct and incorrect answers
Covers all major content areas weighted per exam blueprint
Formatted for easy self-assessment and review
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Pathophysiology 1-60 Cellular adaptation, inflammation, 24%
neoplasia, fluid/electrolyte imbalances,
acid-base disorders
Pharmacology 61-110 Pharmacokinetics, pharmacodynamics, 20%
autonomic nervous system drugs,
cardiovascular agents, antimicrobials
Clinical Assessment & 111-160 History taking, physical examination, 20%
Diagnostic Reasoning diagnostic tests interpretation, differential
diagnosis
Evidence-Based Practice & 161-200 Research designs, evidence appraisal, 16%
Research statistical concepts, applying evidence to
practice
Ethical & Legal Issues 201-225 Informed consent, confidentiality, advanced 10%
directives, malpractice, ethical
decision-making
Health Promotion & Disease 226-250 Screening guidelines, immunization, 10%
Prevention lifestyle counseling, population health
Page 2
,Q1. A 72-year-old patient with atrial fibrillation, hypertension, and type 2 diabetes is on warfarin, lisinopril,
metformin, and atorvastatin. The INR is 4.5. Which intervention is most appropriate?
A. Hold warfarin and administer vitamin K 10 mg orally
B. Hold warfarin and administer fresh frozen plasma
C. Hold warfarin, administer vitamin K 2.5 mg orally, and recheck INR in 24 hours
D. Continue warfarin at reduced dose
Correct Answer: C. Hold warfarin, administer vitamin K 2.5 mg orally, and recheck INR in 24 hours
Rationale: An INR of 4.5 without bleeding warrants holding warfarin and giving low-dose oral vitamin K (1-2.5
mg) to lower INR safely. High-dose vitamin K (10 mg) can cause warfarin resistance. Fresh frozen plasma is
reserved for major bleeding. Continuing warfarin risks hemorrhage.
Why Wrong:
A - High-dose vitamin K can lead to prolonged warfarin resistance and is not indicated without bleeding.
B - Fresh frozen plasma is indicated for serious or life-threatening bleeding, not for an elevated INR without
bleeding.
D - Continuing warfarin with an INR of 4.5 increases bleeding risk; dose reduction is insufficient acutely.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q2. Which of the following best explains why a patient with chronic kidney disease (eGFR 25 mL/min)
requires a lower dose of a drug that is primarily renally eliminated?
A. Increased volume of distribution leads to higher peak concentrations
B. Reduced renal clearance prolongs the elimination half-life
C. Decreased protein binding increases the free fraction of the drug
D. Hepatic metabolism is accelerated, necessitating dose adjustment
Correct Answer: B. Reduced renal clearance prolongs the elimination half-life
Rationale: In chronic kidney disease, reduced glomerular filtration decreases renal drug clearance, prolonging the
elimination half-life. To avoid accumulation and toxicity, doses must be reduced or intervals extended. Increased
volume of distribution (A) is not typical; protein binding changes (C) may occur but are less direct; hepatic
metabolism (D) may be impaired, not accelerated.
Why Wrong:
A - Volume of distribution is often decreased in renal impairment due to fluid shifts, not increased.
C - Decreased protein binding can increase free drug but is not the primary reason for dose adjustment; renal
clearance is the key.
D - Hepatic metabolism is often reduced, not accelerated, in renal disease.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 5
Q3. A patient on digoxin develops nausea, vomiting, and visual disturbances. Serum digoxin level is 3.5
ng/mL. Which of the following interventions is most appropriate?
A. Administer activated charcoal to enhance elimination
B. Administer digoxin immune Fab (Digibind)
C. Increase the dose of digoxin to overcome tolerance
D. Switch to a different cardiac glycoside
Correct Answer: B. Administer digoxin immune Fab (Digibind)
Rationale: Digoxin toxicity at this level with symptoms warrants digoxin immune Fab, which binds digoxin and
reduces free drug. Activated charcoal is not effective for digoxin once absorbed. Increasing dose would worsen
toxicity. Switching glycosides does not address current toxicity.
Why Wrong:
A - Activated charcoal is used for recent ingestion, not for toxicity from chronic therapy after absorption.
C - Increasing dose would exacerbate toxicity; tolerance does not develop to digoxin.
D - Switching to another glycoside is not indicated; management focuses on reversing toxicity.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 38
Q4. A patient is prescribed an ACE inhibitor for hypertension. Which laboratory value should be monitored
before and during therapy?
A. Serum potassium and serum creatinine
B. Serum sodium and serum calcium
C. Liver enzymes and bilirubin
D. Hemoglobin and hematocrit
Correct Answer: A. Serum potassium and serum creatinine
Rationale: ACE inhibitors can cause hyperkalemia and acute kidney injury, especially in patients with renal
impairment or those taking potassium-sparing diuretics. Monitoring serum potassium and creatinine is essential.
Other labs are not typically affected.
Why Wrong:
B - ACE inhibitors do not significantly affect sodium or calcium levels.
C - ACE inhibitors do not cause hepatotoxicity; liver enzymes are not routinely monitored.
D - ACE inhibitors do not cause anemia; hemoglobin/hematocrit are not primary monitoring parameters.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 39
Q5. A patient on a stable dose of warfarin is prescribed a course of metronidazole for a dental infection.
What effect on the INR is expected?
A. Decrease in INR due to increased warfarin metabolism
B. Increase in INR due to inhibition of warfarin metabolism
C. No change in INR because metronidazole does not interact with warfarin
D. Unpredictable effect due to variable absorption
Correct Answer: B. Increase in INR due to inhibition of warfarin metabolism
Rationale: Metronidazole inhibits the hepatic metabolism of warfarin, potentiating its anticoagulant effect and
increasing INR. This interaction is well-documented and requires close monitoring and possible warfarin dose
reduction.
Why Wrong:
A - Metronidazole inhibits, not induces, warfarin metabolism.
C - Metronidazole has a significant interaction with warfarin.
D - The effect is predictable and not due to absorption variability.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q6. A patient with type 2 diabetes and chronic kidney disease (eGFR 45 mL/min) is prescribed metformin.
What is the primary concern?
A. Increased risk of hypoglycemia
B. Risk of lactic acidosis due to accumulation
C. Increased risk of weight gain
D. Reduced efficacy due to renal impairment
Correct Answer: B. Risk of lactic acidosis due to accumulation
Rationale: Metformin is contraindicated when eGFR is <30 mL/min and should be used with caution when eGFR is
30-45 mL/min due to risk of lactic acidosis from drug accumulation. Hypoglycemia is not common with metformin
monotherapy. Weight gain is not typical; metformin is weight-neutral or causes modest weight loss. Efficacy is not
significantly reduced.
Why Wrong:
A - Metformin does not typically cause hypoglycemia; it decreases hepatic glucose production.
C - Metformin is associated with weight neutrality or loss, not gain.
D - Metformin retains efficacy in moderate renal impairment, but safety is the concern.
Page 4
